[go: up one dir, main page]

EE200300311A - Ftalasinoon-piperidinoderivaadid, nende kasutamine ja ravim - Google Patents

Ftalasinoon-piperidinoderivaadid, nende kasutamine ja ravim

Info

Publication number
EE200300311A
EE200300311A EEP200300311A EEP200300311A EE200300311A EE 200300311 A EE200300311 A EE 200300311A EE P200300311 A EEP200300311 A EE P200300311A EE P200300311 A EEP200300311 A EE P200300311A EE 200300311 A EE200300311 A EE 200300311A
Authority
EE
Estonia
Prior art keywords
phthalazinone
medicine
piperidine derivatives
piperidine
derivatives
Prior art date
Application number
EEP200300311A
Other languages
English (en)
Inventor
Grundler Gerhard
Schmidt Beate
Jan Sterk Geert
Hatzelmann Armin
Bundschuh Daniela
Kley Hans-Peter
Timmerman Hendrik
A. M. Christiaans Johannes
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of EE200300311A publication Critical patent/EE200300311A/et
Publication of EE05386B1 publication Critical patent/EE05386B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
EEP200300311A 2001-02-15 2002-02-14 Ftalasinoon-piperidinoderivaadid,ÁnendeÁkasutamineÁjaÁravim EE05386B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01103496 2001-02-15
PCT/EP2002/001547 WO2002064584A1 (en) 2001-02-15 2002-02-14 Phthalayinone-piperidino-derivatives as pde4 inhibitors

Publications (2)

Publication Number Publication Date
EE200300311A true EE200300311A (et) 2003-10-15
EE05386B1 EE05386B1 (et) 2011-02-15

Family

ID=8176497

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300311A EE05386B1 (et) 2001-02-15 2002-02-14 Ftalasinoon-piperidinoderivaadid,ÁnendeÁkasutamineÁjaÁravim

Country Status (22)

Country Link
US (3) US6953853B2 (et)
EP (1) EP1362044A1 (et)
JP (1) JP4301812B2 (et)
KR (1) KR20030074817A (et)
CN (1) CN1524080A (et)
AU (1) AU2002234634B2 (et)
BG (1) BG108124A (et)
BR (1) BR0207278A (et)
CA (1) CA2438520C (et)
CZ (1) CZ20032491A3 (et)
EA (1) EA200300836A1 (et)
EE (1) EE05386B1 (et)
HR (1) HRP20030636B1 (et)
HU (1) HUP0303193A3 (et)
IL (1) IL156812A0 (et)
MX (1) MXPA03007310A (et)
NO (1) NO325245B1 (et)
NZ (1) NZ527424A (et)
PL (1) PL363391A1 (et)
SK (1) SK11382003A3 (et)
WO (1) WO2002064584A1 (et)
ZA (1) ZA200306815B (et)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2438520C (en) * 2001-02-15 2011-10-04 Altana Pharma Ag Phthalazinone-piperidino-derivatives as pde4 inhibitors
EP1429807B1 (en) * 2001-09-19 2007-02-28 ALTANA Pharma AG Combination of a nsaid and a pde-4 inhibitor
WO2004018451A1 (en) * 2002-08-10 2004-03-04 Altana Pharma Ag Pyridazinone-derivatives as pde4 inhibitors
AU2003255376A1 (en) * 2002-08-10 2004-03-11 Altana Pharma Ag Piperidine-derivatives as pde4 inhibitors
HRP20050197A2 (en) * 2002-08-10 2006-06-30 Altana Pharma Ag Piperidine-n-oxide-derivatives
CA2494634A1 (en) * 2002-08-10 2004-03-04 Altana Pharma Ag Piperidine-pyridazones and phthalazones as pde4 inhibitors
HRP20050699A2 (en) * 2003-01-14 2006-11-30 Altana Pharma Ag Pde4 inhibitors for the treatment of neoplasms of lymphoid cells
WO2004098605A1 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Pharmaceutical composition comprising a pde4 inhibitor and il-1 trap
WO2004098578A2 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517
WO2004098633A1 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising a pde-4 inhibitor and a tnf alpha antagonist
WO2004098606A1 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising a pde4 inhibitor and shuil-1r ii
RS52730B (sr) * 2003-05-22 2013-08-30 Takeda Gmbh Kompozicija koja sadrži pde4 inhibitor i pde5 inhibitor
US7776893B2 (en) 2003-09-05 2010-08-17 Nycomed Gmbh Use of PDE4 inhibitors for the treatment of diabetes mellitus
WO2005075456A1 (en) * 2004-02-04 2005-08-18 Altana Pharma Ag 2-(piperidin-4-yl) -4, 5-dihydro-2h-pyridazin-3-one derivatives as pde4 inhibitors
WO2005075457A1 (en) * 2004-02-04 2005-08-18 Altana Pharma Ag Phthalazinone-derivatives as pde4 inhibitors
US20080227790A1 (en) * 2004-02-04 2008-09-18 Altana Pharma Ag Pyridazinone Derivatives and their Use as Pde4 Inhibitors
MX2007010560A (es) 2005-03-08 2008-02-21 Nycomed Gmbh Roflumilast para el tratamiento de diabetes mellitus.
TWI435729B (zh) 2005-11-09 2014-05-01 Combinatorx Inc 治療病症之方法，組合物及套組
EP1984377A2 (en) * 2006-01-17 2008-10-29 Signal Pharmaceuticals LLC Inhibitors of tnf alpha , pde4 and b-raf, compositions thereof and methods of use therewith
CN102772411A (zh) 2006-07-05 2012-11-14 奈科明有限责任公司 用于治疗炎症性肺部疾病的HMG-CoA还原酶抑制剂与磷酸二酯酶4抑制剂的组合
DE602007005167D1 (de) * 2006-12-20 2010-04-15 Glaxo Group Ltd 4-benzyl-1(2h)-phthalazinone als h1-rezeptor-antagonisten
ES2427442T3 (es) 2007-05-16 2013-10-30 Takeda Gmbh Derivados de pirazolona como inhibidores de PDE4
AR074318A1 (es) 2008-11-14 2011-01-05 Nycomed Gmbh Derivados heterociclicos de pirazolona, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades de las vias respiratorias.
PE20140648A1 (es) * 2011-06-17 2014-05-30 Takeda Gmbh Novedosos derivados de ftalazinona-pirrolopirimidinacarboxamida
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
EP3165224A1 (en) 2015-11-09 2017-05-10 Albert-Ludwigs-Universität Freiburg Use of pde4 inhibitors for the prophylaxis and/or therapy of dyslipoproteinaemia and related disorders
JP6820717B2 (ja) 2016-10-28 2021-01-27 株式会社日立ハイテク プラズマ処理装置
CN113121417A (zh) * 2019-12-30 2021-07-16 苏州盛迪亚生物医药有限公司 一种新型哌啶衍生物及其药物用途
WO2021192210A1 (ja) 2020-03-27 2021-09-30 株式会社日立ハイテク 半導体製造方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ244660A (en) * 1991-10-09 1995-05-26 Syntex Inc Pyridopyridazine derivatives and medicaments
CZ141795A3 (en) 1992-12-02 1995-11-15 Pfizer 4-substituted catechol diethers as such and for treating diseases and pharmaceutical preparations based thereon
DE19533975A1 (de) 1995-09-14 1997-03-20 Merck Patent Gmbh Arylalkyl-diazinone
EA002764B1 (ru) * 1997-01-15 2002-08-29 Бык Гульден Ломберг Хемише Фабрик Гмбх Фталазиноны
CZ299304B6 (cs) * 1997-12-15 2008-06-11 Altana Pharma Ag Dihydrobenzofuranové deriváty, jejich farmaceutické použití a farmaceutické prostredky s jejich obsahem
AU1760399A (en) * 1997-12-15 1999-07-05 Byk Gulden Lomberg Chemische Fabrik Gmbh New phthalazinones
EP0934933A1 (en) 1998-02-06 1999-08-11 Byk Gulden Lomberg Chemische Fabrik GmbH Phthalazinones
SI1070056T1 (en) 1998-03-14 2004-12-31 Altana Pharma Ag Phthalazinone pde iii/iv inhibitors
AU7654200A (en) 1999-09-14 2001-04-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Phthalazinone derivatives as pd3/4 inhibitors
EP1228046B1 (en) * 1999-10-25 2007-09-26 Nycomed GmbH Phthalazinone derivatives as pde 4 inhibitors
EA005856B1 (ru) * 1999-10-25 2005-06-30 Алтана Фарма Аг Тетрагидротиопиранфталазиноновые производные в качестве ингибиторов pde4
CZ20023997A3 (cs) 2000-06-05 2003-05-14 Altana Pharma Ag Pyridazinonové deriváty
CA2438520C (en) * 2001-02-15 2011-10-04 Altana Pharma Ag Phthalazinone-piperidino-derivatives as pde4 inhibitors
JP4021329B2 (ja) 2001-04-25 2007-12-12 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング ピペラジノ誘導体およびｐｄｅ４阻害剤としてのその使用
AU2002317733B2 (en) 2001-04-25 2007-12-13 Altana Pharma Ag Phthalazinones derivatives useful as PDE4/7 inhibitors
WO2004018451A1 (en) 2002-08-10 2004-03-04 Altana Pharma Ag Pyridazinone-derivatives as pde4 inhibitors
HRP20050197A2 (en) 2002-08-10 2006-06-30 Altana Pharma Ag Piperidine-n-oxide-derivatives
CA2494634A1 (en) 2002-08-10 2004-03-04 Altana Pharma Ag Piperidine-pyridazones and phthalazones as pde4 inhibitors

Also Published As

Publication number Publication date
US7179810B2 (en) 2007-02-20
AU2002234634B2 (en) 2007-07-26
NZ527424A (en) 2005-02-25
EA200300836A1 (ru) 2004-02-26
HUP0303193A3 (en) 2007-08-28
CN1524080A (zh) 2004-08-25
JP4301812B2 (ja) 2009-07-22
JP2004518727A (ja) 2004-06-24
CA2438520A1 (en) 2002-08-22
EP1362044A1 (en) 2003-11-19
US20070129373A1 (en) 2007-06-07
HRP20030636A2 (en) 2005-06-30
ZA200306815B (en) 2004-06-17
CA2438520C (en) 2011-10-04
WO2002064584A1 (en) 2002-08-22
US20040067946A1 (en) 2004-04-08
NO20033618L (no) 2003-10-15
HRP20030636B1 (en) 2012-05-31
BR0207278A (pt) 2004-02-10
MXPA03007310A (es) 2003-12-04
KR20030074817A (ko) 2003-09-19
HUP0303193A2 (hu) 2003-12-29
CZ20032491A3 (cs) 2004-01-14
US20050234062A1 (en) 2005-10-20
SK11382003A3 (sk) 2004-01-08
US6953853B2 (en) 2005-10-11
IL156812A0 (en) 2004-02-08
EE05386B1 (et) 2011-02-15
BG108124A (bg) 2004-08-31
NO325245B1 (no) 2008-03-10
NO20033618D0 (no) 2003-08-14
US7531540B2 (en) 2009-05-12
PL363391A1 (en) 2004-11-15

Similar Documents

Publication Publication Date Title
EE200300311A (et) Ftalasinoon-piperidinoderivaadid, nende kasutamine ja ravim
EE201300011A (et) Ksantiini derivaadid, nende valmistamine ja kasutamine ravimina
EE04565B1 (et) Adamantaani derivaadid, nende saamine ja kasutamine
EE200100391A (et) Peptidüül-heterotsüklilised ketoonid, nende kasutamine ja farmatseutiline kompositsioon
NO20052855D0 (no) Fosfonoksykinazolinderivater og farmasoytisk anvendelse derav.
EE200200175A (et) Asendatud 2-tio-3,5-ditsüano-4-arüül-6-aminopüridiinid ja nende kasutamine
EE200300048A (et) Bensimidasooli derivaadid, nende valmistamine ja terapeutiline kasutamine
NO20012567D0 (no) Azepinoindolderivater, fremstilling og anvendelse derav
EE200300369A (et) Atsüülitud indanüülamiinid, nende valmistamismeetod, kasutamine ja farmatseutiline preparaat
EE200200251A (et) Uued N-asabitsükloamiidi derivaadid ja nende kasutamine
NO20024175D0 (no) Azetidinderivater, deres fremstilling og farmasöytiske forbindelser inneholdende de samme
EE200300193A (et) Asendatud bensimidasoolid, nende kasutamine ja ravim
EE200300327A (et) Uurea derivaadid, nende valmistamismeetodid, kasutamine ja farmatseutiline kompositsioon
NO20042635L (no) 5-Sulfanyl-ñH-1,2,4-triazol-derivater og deres anvendelse som medisin
EE04497B1 (et) Püridopüranoasepiini derivaadid, nende valmistamine ja terapeutiline kasutamine
DK1095025T3 (da) Benzimidazoler, deres fremstilling og deres anvendelse som lægemidler
EE200200607A (et) 2-atsüülindoolderivaadid ja nende kasutamine kasvajavastaste ravimitena
DK1513836T3 (da) Piperazinylacylpiperidinderivater, fremstilling og terapeutisk anvendelse heraf
DK1590321T3 (da) Arylalkylcarbamat-derivater, fremstilling og terapeutisk anvendelse deraf
DK1417189T3 (da) Acylaminothiazolderivater, fremstilling og terapeutisk anvendelse heraf
DE50209245D1 (de) Neuroprotektives medikament
DK1387838T3 (da) Cyanoanthranylamid-derivater og deres anvendelse som lægemidler
DK1202996T3 (da) Titanforbindelser, fremstilling og anvendelse heraf
DK1556382T3 (da) 3-Phenylpyridoindolderivater, fremstilling og terapeutisk anvendelse deraf
NO20033120D0 (no) 2-arylimino-2,3-dihydrotiazolderivater, fremgangsmater for fremstilling derav og terapeutisk anvendelse derav

Legal Events

Date Code Title Description
HC1A Change of owner name
HC1A Change of owner name
MM4A Lapsed by not paying the annual fees

Effective date: 20140214